Leo Innovation Lab, the digital innovation arm of Denmark-based skincare product maker Leo Pharma, has supplied $5.5m in seed and series A funding to a total of five startups.
The recipients include Remedly, the US-based creator of a cloud-based platform that helps dermatologists run their practices, and Pacifica, a US-headquartered developer of a range of app-based mental health management tools.
TalkLife, the UK-based operator of a mental health-focused social network, also received funding, as did Finland-based diagnostics technology developer Combinostics and SkinVision, the creator of an app that helps users detect skin cancer.
Kristian Hart-Hansen, Leo Innovation Lab’s CEO, said:; “Digital disruption is happening in our market, and we intend to play a pivotal role in setting the agenda for pharma and healthcare innovation by helping startups hatch and commercialise new ideas.
“The companies chosen for seed investment were carefully selected for their ability to digitally disrupt the industry, and to align with our patient-centric vision and values about holistic healthcare.”